{"document_type": "article", "snippet": "The embattled $40 billion pharmaceuticals company tried \u2013 but failed \u2013 to quell concerns about its convoluted dealings with distributors.", "type_of_material": "News", "web_url": "http://www.nytimes.com/2015/10/27/business/dealbook/video-valeant-effort.html", "subsection_name": "DealBook", "blog": [], "section_name": "Business Day", "source": "The New York Times", "pub_date": "2015-10-27T00:00:00Z", "word_count": "27", "slideshow_credits": null, "news_desk": "Business", "byline": {"original": "By REUTERS", "person": [], "organization": "REUTERS"}, "abstract": null, "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "rank": "1", "name": "organizations", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "rank": "2", "name": "subject", "is_major": "N"}], "print_page": null, "multimedia": [], "lead_paragraph": "The embattled $40 billion pharmaceuticals company tried \u2013 but failed \u2013 to quell concerns about its convoluted dealings with distributors.", "headline": {"content_kicker": "Breakingviews", "main": "Video: Valeant Effort"}, "_id": "562e664338f0d82f94187bfe"}